Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
5
×
clinical trials
life sciences
national blog main
national top stories
biotech
boston
new york blog main
atlas venture
deals
gene therapy
san diego blog main
san francisco blog main
startups
adeno-associated virus
akcea therapeutics
alexion pharmaceuticals
allosteric
alnylam pharmaceutials
anylam pharmaceuticals
arrowhead pharmaceuticals
astellas pharma
atopic dermatitis
audentes therapeutics
autoimmune disorders
avidity biosciences
bluebird bio
boehringer ingelheim
brace pharma
cancer
cardiomyopathy
chemotherapy
cisplatin
cleva pharma
decibel therapeutics
dicerna pharmaceuticals
drug discovery
drugs
duchenne muscular dystrophy
What
ago
5
×
medicines
5
×
therapeutics
disease
drug
genetic
long
rare
years
abandoning
adding
address
adds
aiming
akcea
allosteric
alnylam
amyloidosis
approved
attr
available
baggage
balance
battle
biotechs
build
clinic
companies
considering
cuts
data
deal
debilitating
decibel
development
dicerna
diseases
drugs
dyne
early
Language
unset
Current search:
ago
×
medicines
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M